Assembly Biosciences (NASDAQ:ASMB) Receives “Neutral” Rating from HC Wainwright

HC Wainwright restated their neutral rating on shares of Assembly Biosciences (NASDAQ:ASMB) in a research note published on Thursday morning, Benzinga reports.

Separately, StockNews.com upgraded shares of Assembly Biosciences from a hold rating to a buy rating in a report on Friday, May 10th.

Assembly Biosciences Stock Up 1.7 %

ASMB stock opened at $15.39 on Thursday. The firm’s fifty day moving average is $14.24 and its 200 day moving average is $12.24. Assembly Biosciences has a 52 week low of $7.69 and a 52 week high of $20.04.

Assembly Biosciences (NASDAQ:ASMB) last posted its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($1.66) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.74) by $1.08. The business had revenue of $5.79 million during the quarter. On average, research analysts forecast that Assembly Biosciences will post -12.65 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director John G. Mchutchison sold 2,117 shares of the firm’s stock in a transaction on Thursday, May 23rd. The shares were sold at an average price of $14.93, for a total transaction of $31,606.81. Following the sale, the director now directly owns 19,104 shares in the company, valued at approximately $285,222.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders have sold 7,580 shares of company stock valued at $102,979. Insiders own 5.10% of the company’s stock.

Institutional Investors Weigh In On Assembly Biosciences

A hedge fund recently bought a new stake in Assembly Biosciences stock. Acuitas Investments LLC acquired a new stake in Assembly Biosciences, Inc. (NASDAQ:ASMB) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 265,585 shares of the biopharmaceutical company’s stock, valued at approximately $218,000. Acuitas Investments LLC owned 0.40% of Assembly Biosciences at the end of the most recent reporting period. Hedge funds and other institutional investors own 19.92% of the company’s stock.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.